

**Table 1 (appendix-online publication only). Anti-HCV seroprevalence studies in diabetic population.**

	<b>DM (n)</b>	<b>Anti- HCV(+)</b>	<b>CONTROL (n)</b>	<b>Anti- HCV (+)</b>	<b>p</b>
<b>Özyilkan et al, 1994</b> <sup>15</sup>	100 - 25 type 1 - 75 type 2	8 % - 0% - 10.6%	-	-	-
<b>Gray et al, 1995</b> <sup>16</sup>	200 type 2	8 %	-	-	-
<b>Simó et al, 1996</b> <sup>17</sup> [†]	176 - 60 type 1 - 116 type 2	11,5 % - 6.6% - 12.1%	6172	2.5 %	<0.001
<b>Rudoni et al, 1999</b> <sup>18</sup> [†]	259 - 45 type 1 - 214 type 2	3,09 % - 0 % - 3.73 %	14100	0.04 %	<0.001
<b>Mason et al, 1999</b> <sup>19</sup> [†][‡]	596	4.2%	377	1.6 %	0.02
<b>Sotiropoulos et al, 1999</b> <sup>20</sup>	423 - 30 type 1 - 393 type 2	1.65 % - 0 % - 1.78 %	-	-	-
<b>Ryu et al, 2001</b> <sup>21</sup> [*]	627	2.1 %	-	-	-
<b>Okan et al, 2002</b> <sup>22</sup> [†]	692 type 2	7.5%	1014	0.1%	<0.0001

[\*]: not specified the percentage of each type of diabetes; [†]: Blood donors used as control group; [‡]: subjects with thyroid disease undergoing thyroid scan used as control group. **DM**: diabetes mellitus.